• 1
    Schaible HG, Jarrott B, Hope PJ, Duggan AW. Release of immunoreactive Substance P in the spinal cord during development of acute arthritis in the knee joint of the cat: a study with antibody microprobes. Brain Res 1990; 529: 21423.
  • 2
    Laird JMA, Olivar T, Roza C, De Felipe C, Hunt SP, Cervero F. Deficits in visceral pain and hyperalgesia of mice with a disruption of the tachykinin NK1 receptor gene. Neuroscience 2000; 98: 34552.
  • 3
    Bradesi S, Eutamene H, Fioramonti J, Bueno L. Acute restraint stress activates functional NK1 receptor in the colon of female rats: involvement of steroids. Gut 2002; 50: 34954.
  • 4
    Salter MW, Henry JL. Responses of functionally identified neurones in the dorsal horn of the cat spinal cord to Substance P, neurokinin A and physalaemin. Neuroscience 1991; 43: 60110.
  • 5
    Honore P, Menning PM, Rogers SD, et al. Spinal Substance P receptor expression and internalization in acute, short-term, and long-term inflammatory pain states. J Neurosci 1999; 19: 76708.
  • 6
    Abbadie C, Brown JL, Mantyh PW, Basbaum AI. Spinal cord Substance P receptor immunoreactivity increases in both inflammatory and nerve injury models of persistent pain. Neuroscience 1996; 70: 2019.
  • 7
    Ishigooka M, Zermann D-H, Doggweiler R, Schmidt RA, Hashimoto T, Nakada T. Spinal NK1 receptor is upregulated after chronic bladder irritation. Pain 2001; 93: 4350.
  • 8
    Mantyh PW, Rogers SD, Honore P, et al. Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the Substance P receptor. Science 1997; 278: 2759.
  • 9
    De Felipe C, Herrero JF, O'Brien JA, et al. Altered nociception, analgesia and aggression in mice lacking the receptor for Substance P. Nature 1998; 392: 3947.
  • 10
    Zimmer A, Zimmer AM, Baffi J, et al. Hypoalgesia in mice with a targeted deletion of the tachykinin 1 gene. Proc Natl Acad Sci U S A 1998; 95: 26305.
  • 11
    Birch PJ, Harrison SM, Hayes AG, Rogers H, Tyers MB. The non-peptide NK1 receptor antagonist, (+/-)-CP-96,345, produces antinociceptive and anti-oedema effects in the rat. Br J Pharmacol 1992; 105: 50810.
  • 12
    Tsuchiya M, Sakakibara A, Yamamoto M. A tachykinin NK1 receptor antagonist attenuates the 4 beta-phorbol-12-myristate-13-acetate-induced nociceptive behaviour in the rat. Eur J Pharmacol 2005; 507: 2934.
  • 13
    Kamp EH, Beck DR, Gebhart GF. Combinations of neurokinin receptor antagonists reduce visceral hyperalgesia. J Pharmacol Exp Ther 2001; 299: 10513.
  • 14
    Okano S, Ikeura Y, Inatomi N. Effects of tachykinin NK1 receptor antagonists on the viscerosensory response caused by colorectal distention in rabbits. J Pharmacol Exp Ther 2002; 300: 92531.
  • 15
    Greenwood-Van Meerveld B, Gibson MS, Johnson AC, Venkova K, Sutkowski-Markmann D. NK1 receptor-mediated mechanisms regulate colonic hypersensitivity in the guinea pig. Pharmacol Biochem Behav 2003; 74: 100513.
  • 16
    Gaudreau G-A, Plourde V. Role of tachykinin NK1, NK2 and NK3 receptors in the modulation of visceral hypersensitivity in the rat. Neurosci Lett 2003; 351: 5962.
  • 17
    Bradesi S, Eutamene H, Garcia-Villar R, Fioramonti J, Bueno L. Stress-induced visceral hypersensitivity in female rats is estrogen-dependent and involves tachykinin NK1 receptors. Pain 2003; 102: 22734.
  • 18
    Hill R. NK1 (Substance P) receptor antagonists – why are they not analgesic in humans? Trends Pharmacol Sci 2000; 21: 2446.
  • 19
    Perry MJ, Lawson SN. Differences in expression of oligosaccharides, neuropeptides, carbonic anhydrase and neurofilament in rat primary afferent neurons retrogradely labelled via skin, muscle or visceral nerves. Neuroscience 1998; 85: 293310.
  • 20
    Brown JL, Liu H, Maggio JE, Vigna SR, Mantyh PW, Basbaum AI. Morphological characterization of Substance P receptor-immunoreactive neurons in the rat spinal cord and trigeminal nucleus caudalis. J Comp Neurol 1995; 356: 32744.
  • 21
    Sarkar S, Aziz Q, Woolf CJ, Hobson AR, Thompson DG. Contribution of central sensitisation to the development of non-cardiac chest pain. Lancet 2000; 356: 11549.
  • 22
    Sarkar S, Hobson AR, Furlong PL, Woolf CJ, Thompson DG, Aziz Q. Central neural mechanisms mediating human visceral hypersensitivity. Am J Physiol Gastrointest Liver Physiol 2001; 281: G1196202.
  • 23
    Willert RP, Woolf CJ, Hobson AR, Delaney C, Thompson DG, Aziz Q. The development and maintenance of human visceral pain hypersensitivity is dependent on the N-methly-D-aspartate receptor. Gastroenterology 2004; 126: 68392.
  • 24
    Sarkar S, Hobson AR, Hughes A, et al. The prostaglandin E2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans. Gastroenterology 2003; 124: 1825.
  • 25
    Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in clinical research. Br Med J 1990; 300: 2305.
  • 26
    Kemp JA, McKernan RM. NMDA receptor pathways as drug targets. Nat Neurosci 2002; 5 (Suppl.): 103942.
  • 27
    Palmer JA, De Felipe C, O'Brien JA, Hunt SP. Disruption of the Substance P receptor (neurokinin-1) gene does not prevent upregulation of preprotachykinin-A mRNA in the spinal cord of mice following peripheral inflammation. Eur J Neurosci 1999; 11: 35318.
  • 28
    Traub RJ. The spinal contribution of Substance P to the generation and maintenance of inflammatory hyperalgesia in the rat. Pain 1996; 67: 15161.
  • 29
    Nichols ML, Allen BJ, Rogers SD, et al. Transmission of chronic nociception by spinal neurons expressing the Substance P receptor. Science 1999; 286: 155861.
  • 30
    Laird JMA, Roza C, De Felipe C, Hunt SP, Cervero F. Role of central and peripheral tachykinin NK1 receptors in capsaicin-induced pain and hyperalgesia in mice. Pain 2001; 90: 97103.
  • 31
    Okano S, Nagaya H, Ikeura Y, Natsugari H, Inatomi N. Effects of TAK-637, a novel neurokinin-1 receptor antagonist, on colonic function in vivo. J Pharmacol Exp Ther 2001; 298: 55964.
  • 32
    Boyce S, Hill R. Discrepant Results from Preclinical and Clinical Studies on the Potential of Substance P Receptor Antagonist Compounds as Analgesics. Proc 9th World Congress on Pain. Seattle: IASP Press, 2000.
  • 33
    Beresford IJ, Hagan RM, Ireland SJ. Investigation into species variants in tachykinin NK1 receptors by use of the non-peptide antagonist, CP-96,345. Br J Pharmacol 1991; 104: 2923.
  • 34
    Smith DW, Hewson L, Fuller P, Williams AR, Wheeldon A, Rupniak NM. The Substance P antagonist L-760,735 inhibits stress-induced NK(1) receptor internalisation in the basolateral amygdala. Brain Res 1999; 848: 905.
  • 35
    Santarelli L, Gobbi G, Debs PC, et al. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc Natl Acad Sci U S A 2001; 98: 19127.
  • 36
    Hietala J. PET imaging of NK-1 receptors in living human brain. Int J Neuropsychopharmacol 2000; 3: 6062.
  • 37
    Lecci A, Capriati A, Maggi CA. Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrome. Br J Pharmacol 2004; 141: 124963.
  • 38
    Woolf CJ, Thompson SW. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain 1991; 44: 2939.
  • 39
    Chen L, Huang LY. Protein kinase C reduces Mg2+ block of NMDA-receptor channels as a mechanism of modulation. Nature 1992; 356: 5213.
  • 40
    Cao YQ, Mantyh PW, Carlson EJ, Gillespie AM, Epstein CJ, Basbaum AI. Primary afferent tachykinins are required to experience moderate to intense pain. Nature 1998; 392: 3904.